Health Canada approves Orladeyo the only oral treatment for the prevention of hereditary angioedema attacks.- Biocryst
BioCryst Pharmaceuticals, Inc. announced that Health Canada has approved oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
Orladeyo was safe and well tolerated in clinical trials. The most frequently reported adverse reactions in patients receiving Orladeyo compared with placebo were gastrointestinal reactions. These reactions generally occurred early after initiation of treatment with Orladeyo, became less frequent with time and typically self-resolved..
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins